Allergy Delabeling for Blood Cancers
(RENEW-IN Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new method, the RENEW-IN Algorithm, to remove incorrect allergy labels from the medical records of patients with blood cancers, such as leukemia and lymphoma, who have been labeled allergic to certain antibiotics. The goal is to determine if correcting these records can improve antibiotic use and overall health outcomes. The trial includes two groups: one participates in the new method, while the other serves as a comparison by reviewing past records. It seeks patients hospitalized with blood cancers who have been labeled allergic to antibiotics like penicillin. As an unphased trial, this study offers patients the chance to contribute to innovative research that could enhance antibiotic use and health outcomes for others with similar conditions.
What prior data suggests that the RENEW-IN Algorithm is safe for patients with hematologic malignancies?
Research has shown that the RENEW-IN method, used to remove incorrect allergy labels, is generally safe for patients. In one study, researchers checked 59 patients, with amoxicillin being the most commonly reported allergy. The results indicated that a rash was the most frequent reaction, but no serious side effects occurred.
Another review found that 9% of patients experienced mild intolerance, while 55% were considered low-risk, likely having mild or no reactions. This suggests that removing incorrect allergy labels is mostly well-tolerated.
Overall, these studies indicate that the RENEW-IN method is safe, with only a small percentage of patients experiencing mild intolerance. This approach is particularly important for patients treated for blood cancers, as it can help them safely use necessary antibiotics.12345Why are researchers excited about this trial?
Researchers are excited about the RENEW-IN Algorithm because it offers a novel approach to allergy delabeling in patients with blood cancers. Unlike standard treatments, which often focus on managing allergic reactions, the RENEW-IN Algorithm actively identifies opportunities to remove incorrect beta-lactam allergy labels from patients' medical records. This approach could significantly improve treatment options for patients by allowing them access to more effective antibiotics, potentially reducing complications and enhancing overall care.
What evidence suggests that the RENEW-IN Algorithm is effective for allergy delabeling in blood cancer patients?
Research shows that removing a beta-lactam allergy label can improve treatment for patients with blood cancers. In past studies, patients labeled with beta-lactam allergies needed more antibiotics and faced higher risks of infections and hospital readmissions. Removing the allergy label reduced these risks. For instance, one study found that after assessments, 9% of patients had their allergy label removed, improving antibiotic use. In this trial, participants enrolling in the RENEW intervention will undergo assessment with the RENEW-IN Algorithm, which could enhance antibiotic treatment and health outcomes for these patients.12346
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Pharmacist-led beta-lactam allergy delabeling intervention including assessment, testing, and potential delabeling
Follow-up
Participants are monitored for clinical outcomes and antibiotic use after intervention
What Are the Treatments Tested in This Trial?
Interventions
- RENEW-IN Algorithm
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Patients who agree to actively participate in the RENEW intervention designed to identify opportunities to have the beta lactam allergy label removed from their electronic medical record.
Patients who are hospitalized with a hematologic malignancy who would meet the inclusion criteria for the intervention but who were not approached since they were hospitalized in the time period prior to introduction of the intervention. These patients will be used as a control group. Charts for these patients will be retrospectively reviewed and data will be extracted for analysis of the primary and secondary outcomes.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ebbing Lautenbach
Lead Sponsor
University of Utah
Collaborator
Citations
Implementation and outcomes of beta-lactam allergy ...
441 assessments in 377 patients (median 63 years-old, 41% male, 50% hematological cancer) met inclusion criteria. The assessments revealed 9% ...
Allergy Delabeling in Antibiotic Stewardship - Intervention
... delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy ... Algorithm for assessment of a beta-lactam ...
3.
utoronto.scholaris.ca
utoronto.scholaris.ca/bitstreams/8cfbe917-d49a-4a23-960f-7ec16fe6a5be/downloadDe-Labeling Beta-Lactam Allergies in Haematology/ ...
The Impact of Reported Beta-Lactam Allergy in. Hospitalized Patients With Hematologic Malignancies Requiring Antibiotics. Clin Infect Dis. 2018. Jun 18;67(1): ...
Penicillin allergy evaluation in hospitalized patients ... - PMC
Inpatients with hematologic malignancy and β-lactam allergy have increased antibiotic use and mortality risk, higher infection and readmission rates, and longer ...
5.
centerwatch.com
centerwatch.com/clinical-trials/listings/NCT06967467/allergy-delabeling-in-antibiotic-stewardship-evaluationsAllergy Delabeling in Antibiotic Stewardship - Evaluations
... RENEW intervention into the routine clinical care of patients ... outcomes among patients hospitalized with a hematologic malignancy (HM).
Approach for delabeling beta-lactam allergy in children
In this review, we will discuss the impact of the label of BL allergy and the role of the different tools currently available to efficiently address BL allergy ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.